Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
European Journal of Gastroenterology & Hepatology
|
July 3, 2014
Colon capsule endoscopy is a safe and useful tool to assess disease parameters in patients with ulcerative colitis
Mileidis San Juan-Acosta, Angel Caunedo-Álvarez, Federico Argüelles-Arias, et al.
Therapeutic Advances in Gastroenterology
|
September 11, 2024
High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease
Jaime González-Antuña, Teresa Valdés-Delgado, Belén Maldonado-Pérez, et al.
World Journal of Gastroenterology
|
December 25, 2018
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, et al.
Therapeutic Advances in Gastroenterology
|
July 2, 2019
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, et al.
Revista Espanola De Enfermedades Digestivas
|
January 4, 2021
Ustekinumab in Crohn's disease: real-world outcomes and predictors of response
Laura Lorenzo González, Teresa Valdés Delgado, Juan María Vázquez Morón, et al.
Inflammatory Bowel Diseases
|
July 31, 2024
Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing
Federico Argüelles-Arias, F Javier Rodriguez González, Jaime González Antuña, et al.
Revista Espanola De Enfermedades Digestivas
|
August 5, 2017
Evolution of the incidence of inflammatory bowel disease in Southern Spain
Dina Chaaro Benallal, María Fernanda Guerra Veloz, Federico Argüelles-Arias, et al.
Revista Espanola De Enfermedades Digestivas
|
June 13, 2018
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
María Fernanda Guerra Veloz, Juan María Vázquez Morón, María Belvis Jiménez, et al.
Revista Espanola De Enfermedades Digestivas
|
March 1, 2012
Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
Federico Argüelles-Arias, Luisa Castro-Laria, Manuel Barreiro-de Acosta, et al.
European Journal of Gastroenterology & Hepatology
|
September 14, 2017
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Federico Argüelles-Arias, Maria Fernanda Guerra Veloz, Raul Perea Amarillo, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
European Journal of Gastroenterology & Hepatology
|
July 3, 2014
Colon capsule endoscopy is a safe and useful tool to assess disease parameters in patients with ulcerative colitis
Mileidis San Juan-Acosta, Angel Caunedo-Álvarez, Federico Argüelles-Arias, et al.
Therapeutic Advances in Gastroenterology
|
September 11, 2024
High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease
Jaime González-Antuña, Teresa Valdés-Delgado, Belén Maldonado-Pérez, et al.
World Journal of Gastroenterology
|
December 25, 2018
Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
María Fernanda Guerra Veloz, Federico Argüelles-Arias, Luisa Castro Laria, et al.
Therapeutic Advances in Gastroenterology
|
July 2, 2019
Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data
María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, et al.
Revista Espanola De Enfermedades Digestivas
|
January 4, 2021
Ustekinumab in Crohn's disease: real-world outcomes and predictors of response
Laura Lorenzo González, Teresa Valdés Delgado, Juan María Vázquez Morón, et al.
Inflammatory Bowel Diseases
|
July 31, 2024
Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing
Federico Argüelles-Arias, F Javier Rodriguez González, Jaime González Antuña, et al.
Revista Espanola De Enfermedades Digestivas
|
August 5, 2017
Evolution of the incidence of inflammatory bowel disease in Southern Spain
Dina Chaaro Benallal, María Fernanda Guerra Veloz, Federico Argüelles-Arias, et al.
Revista Espanola De Enfermedades Digestivas
|
June 13, 2018
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
María Fernanda Guerra Veloz, Juan María Vázquez Morón, María Belvis Jiménez, et al.
Revista Espanola De Enfermedades Digestivas
|
March 1, 2012
Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
Federico Argüelles-Arias, Luisa Castro-Laria, Manuel Barreiro-de Acosta, et al.
European Journal of Gastroenterology & Hepatology
|
September 14, 2017
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
Federico Argüelles-Arias, Maria Fernanda Guerra Veloz, Raul Perea Amarillo, et al.
Page
of 3